2D QSAR study for gemfibrozil glucuronide as the mechanism-based inhibitor of CYP2C8

Indian Journal of Pharmaceutical Sciences

Volumn 75, Issue 6, 2013, Pages 680-687

  Taxak, N ^a,b   Bharatam, P V ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b AMITY UNIVERSITY   (India)

Author keywords

2D descriptors; CYP2C8; Gemfibrozil; glucuronide conjugation; mechanism based inhibition; QSAR

Indexed keywords

AMODIAQUINE; CYTOCHROME P450 2C8; GEMFIBROZIL ACYL BETA GLUCURONIDE; GEMFIBROZIL GLUCURONIDE CONJUGATE; SUGAR ACID; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; LIVER MICROSOME; MECHANISM BASED INHIBITION; N DEETHYLATION; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 84892689233     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. de Montellano PR, editor. Cytochrome P450: Structure, mechanism, and biochemistry. New York: Kluwer Academic/Plenum Publishers; 2005.
2. Lee J, Obach RS, Fisher MB, editors. Drug metabolizing enzymes: Cytochrome P450 and other enzymes in drug discovery and development. New York: Marcel Dekker Inc. ; 2005.
3. Kalgutkar AS, Didiuk MT. Structural alerts, reactive metabolites, and protein covalent binding: How reliable are these attributes as predictors of drug toxicity? Chem Biodivers 2009;6:2115-37.
4. Kalgutkar AS, Dalvie D, Obach RS, Smith DA, editors. Reactive Drug Metabolites. New York: John Wiley and Sons; 2012.
5. Taxak N, Bharatam PV. An insight into the concept and details of mechanism-based inhibition of CYP450. Curr Res Inform Pharm Sci 2010;11:62-7.
6. Taxak N, Patel B, Bharatam PV. Carbene generation by cytochromes and electronic structure of heme-iron-porphyrin-carbene complex: A quantum chemical study. Inorg Chem 2013;52:5097-109.
7. Taxak N, Desai PV, Patel B, Mohutsky M, Klimkowski VJ, Gombar V, et al. Metabolic-intermediate complex formation with Cytochrome P450: Theoretical studies in elucidating the reaction pathway for the generation of reactive nitroso intermediate. J Comput Chem 2012;33:1740-7.
8. Orr ST, Ripp SL, Ballard TE, Henderson JL, Scott DO, Obach RS, et al. Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-Activity relationships and discovery strategies to mitigate drug-Drug interaction risks. J Med Chem 2012;55:4896-933.
9. Wang JS, Neuvonen M, Wen X, Backman JT, Neuvonen PJ. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 2002;30:1352-6.
10. Mano Y, Usui T, Kamimura H. The UDP-Glucuronosyltransferase 2B7 Isozyme Is Responsible for Gemfibrozil Glucuronidation in the Human Liver. Drug Metab Dispos 2007;35:2040-4.
11. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: Implications for drug-drug interactions. Drug Metab Dispos 2006;34:191-7.
12. Jenkins SM, Zvyaga T, Johnson SR, Hurley J, Wagner A, Burrell R, et al. Studies to further investigate the inhibition of human liver microsomal CYP2C8 by the acyl-?-glucuronide of gemfibrozil. Drug Metab Dispos 2011;39:2421-30.
13. Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Mechanism-based inactivation of CYP2C8 by Gemfibrozil occurs rapidly in humans. Clin Pharmacol Ther 2011;89:579-86.
14. Baer BR, DeLisle RK, Allen A. Benzylic oxidation of gemfibrozil-1-Obeta- glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition. Chem Res Toxicol 2009;22:1298-309.
15. Dearden JC. In silico prediction of drug toxicity. J Comput Aided Mol Des 2003;17:119-27.
16. Gramatica P. Principles of QSAR models validation: Internal and external. QSAR Comb Sci 2007;26:694-701.
17. Perkins R, Fang H, Tong W, Welsh WJ. Quantitative structure-activity relationship methods: Perspectives on drug discovery and toxicology. Environ Toxicol Chem 2003;22:1666-79.
18. Deeb O. Recent applications of quantitative structure-Activity relationships in drug design. In: Ekinci D, editor. Biochemistry, genetics and molecular biology, medicinal chemistry and drug design. Rijeka, Croatia: InTech; 2012. Available from: http://www. intechopen. com/books/medicinal-chemistry- and-drug-design/recent-applications-ofquantitative-structure-activity- relationships-in-drug-design [Last accesed on 2013 Oct 02].
19. Accelrys Software Inc. , Discovery Studio Modeling Environment, Release 3. 5, San Diego: Accelrys Software Inc. , 2012.
20. Sybyl7. 1, Gasteiger J, Todeschini R, Mauri A, Livingstone D, Ertl P, et al. Virtual computational chemistry laboratory-design and description. J Comput Aided Mol Des 2005;19:453-63.
21. Joshi UJ, Tikhele SH, Shah FH. 2D QSAR of arylpiperazines as 5-HT1A receptor agonists. Indian J Pharm Sci 2007;69:800-4.
22. Khan N, Soni LK, Gupta AK, Wakode SR, Wagh RD, Kashedikar SG. QSAR analysis of N-Alkyl imidazole analogues as antibacterial agents. Indian J Pharm Sci 2006;68:341-6.
23. Kirubakaran P, Muthusamy K, Singh KH, Nagamani S. Ligand-based pharmacophore modeling; atom-based 3D-QSAR analysis and molecular docking studies of phosphoinositide-dependent kinase-1 inhibitors. Indian J Pharm Sci 2012;74:141-51.
24. Rogers D, Hopfinger AJ. Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure property relationships. J Chem Inf Comput Sci 1994;34:854-66.